Abstract
Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs.
Highlights
Lung cancer is the major cause of cancer death and one of the leading causes of death worldwide.In 2018, it accounted for more than 2 million deaths, according to the data reported by the World HealthOrganization (WHO) [1]
This review aims to discuss different available strategies for the treatment of Non-small cell lung cancer (NSCLC)
The number of available treatments for NSCLC continues to expand, driven by the improvements introduced by nanotechnology
Summary
Lung cancer is the major cause of cancer death and one of the leading causes of death worldwide. NSCLC affects a much broader range of the population and accounts for 80% of all lung cancer cases. This type of cancer includes adenocarcinoma, squamous cell carcinoma, and different histotypes of large cell carcinoma (Table 1). It is a subtype presenting components of both adenocarcinoma and squamous cellaffects carcinoma It usually the Centrally located in the larger bronchi of the peripherical part of the lung. The development of NSCLC vaccines has arisen in recent years, supported by the design of nanoparticles addressed against a cell population, such as dendritic cells [37], to awake a controlled immune response against the tumor. We will provide a complete study of the current therapies for NSCLC and a further understanding of nanomedicine in this field
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
